Alliance Discussion with Andi Fristedt, FDA

What are FDA’s 2023 priorities under the new drug and medical device user fee bills? What exactly was included about clinical trial diversity in December’s Omnibus legislation? FDA Deputy Commissioner for Policy, Legislation and International Affairs, Andi Fristedt, joined us to share an inside look at key issues impacting patients, researchers, and industry. Watch the recording.